Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/12
A61K-039/215
C12P-019/34
C12P-021/04
C12P-021/06
C12N-015/09
C12N-015/63
C12N-015/64
C12N-015/66
출원번호
US-0873424
(2004-06-21)
등록번호
US-8541003
(2013-09-24)
발명자
/ 주소
Anderson, D. Karl
Holtz-Corris, Kathleen M.
Chubet, Rick
Adams, Daniel
Cox, Manon
출원인 / 주소
Protein Sciences Corporation
대리인 / 주소
Vedder Price P.C.
인용정보
피인용 횟수 :
1인용 특허 :
41
초록▼
SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid v
SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
대표청구항▼
1. A recombinant baculovirus vector that expresses: (a) a baculovirus signal peptide; and(b) a SARS S protein,wherein expression of the SARS S protein is under control of a polyhedrin promoter. 2. The recombinant baculovirus vector of claim 1, wherein the baculovirus signal peptide comprises an amin
1. A recombinant baculovirus vector that expresses: (a) a baculovirus signal peptide; and(b) a SARS S protein,wherein expression of the SARS S protein is under control of a polyhedrin promoter. 2. The recombinant baculovirus vector of claim 1, wherein the baculovirus signal peptide comprises an amino acid sequence Met Pro Leu Tyr Lys Leu Leu Asn Val Leu Trp Leu Val Ala Val Ser Asn Ala Ile (SEQ ID NO: 28). 3. A recombinant baculovirus vector that comprises: an isolated nucleic acid comprising a nucleotide sequence GCCCTTGTAC AAATTGTTAA ACGTTTTGTG GTTGGTCGCC GTTTCTAACG CGAT (SEQ ID NO: 29) encoding a baculovirus signal peptide,wherein the recombinant baculovirus vector also expresses a SARS S protein,wherein expression of the SARS S protein is under control of a polyhedrin promoter. 4. The recombinant baculovirus vector of claim 1 or 3, wherein the polyhedrin promoter is Autographa californica Nuclear Polyhedrosis Virus AcNPV. 5. The recombinant baculovirus vector of claim 1 or 3, wherein the SARS S protein is truncated. 6. An immunogenic composition comprising the recombinant baculovirus vector of claim 1 or 3. 7. An immunogenic composition comprising the recombinant baculovirus vector of claim 1 or 3, further comprising a carrier or diluent and/or adjuvant. 8. An immunogenic composition comprising the recombinant baculovirus vector of claim 1 or 3 in an aerosolizer or aerosol form, or a pump spray dispenser, thereby permitting intranasal administration of the immunogenic composition. 9. A method for producing a biologically active, highly pure, recombinant SARS S protein, comprising: (a) infecting insect cells that grow in serum-free media with a recombinant baculovirus that comprises DNA coding for SARS S protein such that the SARS S protein is expressed recombinantly;(b) culturing the infected insect cells in serum-free media; and(c) purifying the recombinant SARS S protein to 95% or greater purity, wherein:the biologically active, highly pure, recombinant SARS S protein is produced; andis biologically active such that it agglutinates red blood cells. 10. The method of claim 9, wherein the SARS S protein consists essentially of an S1 protein. 11. The method of claim 9, wherein the SARS S protein consists essentially of an S2 protein. 12. The method of claim 9, wherein the baculovirus is Autographa californica Nuclear Polyhedrosis Virus (AcNPV). 13. The method of claim 12, wherein the DNA coding for the SARS S protein is under the control of a AcNPV polyhedrin promoter. 14. The method of claim 13, wherein the SARS S protein is expressed with a baculovirus signal peptide. 15. The method of claim 13 or 14, wherein the SARS S protein is expressed with a His tag. 16. The method of claim 14, wherein DNA coding for the baculovirus signal peptide is seamlessly joined to the DNA coding for the SARS S protein, without addition of a signal nucleotide. 17. The method of claim 16, wherein the recombinant baculovirus is prepared by a transfer vector, wherein the transfer vector is produced by a process comprising: (a) cutting an initial vector having DNA coding for a leader sequence and a restriction site at a distance from the restriction site by an enzyme that so cuts, whereby the restriction site is excised from the initial vector, and the initial vector has a unique sticky end;(b) performing in a separate reaction a nucleic acid amplification reaction of DNA coding for the SARS S protein to obtain an amplification product, whereby the restriction site is part of the amplification product;(c) cutting the amplification product with the enzyme, whereby the amplification product has a unique sticky end; and(d) ligating the initial vector having the unique sticky end and the amplification product having the unique sticky end such that the transfer vector is obtained and intervening nucleic acid molecules between the DNA coding for the leader sequence and the DNA encoding the SARS S protein are avoided. 18. The method of claim 17, wherein the enzyme is Sapl. 19. The method of claim 17, wherein the amplification reaction is a polymerase chain reaction. 20. A method for preparing a baculovirus transfer vector for preparing a recombinant baculovirus that expresses a heterologous protein and a baculovirus signal peptide, wherein DNA coding for the heterologous protein is seamlessly joined to DNA coding for the baculovirus signal peptide, without addition of a single nucleotide, comprising: (a) cutting an initial vector having DNA coding for a leader sequence and a restriction site at a distance from the restriction site by an enzyme that so cuts, whereby the restriction site is excised from the initial vector, and the initial vector has a unique sticky end;(b) performing in a separate reaction a nucleic acid amplification reaction of DNA coding for the SARS S protein to obtain an amplification product, whereby the restriction site is part of the amplification product;(c) cutting the amplification product with the enzyme, whereby the amplification product has a unique sticky end; and(d) ligating the initial vector having the unique sticky end and the amplification product having the unique sticky end such that the transfer vector is obtained and intervening nucleic acid molecules between the DNA coding for the leader sequence and the DNA encoding the SARS S protein are avoided.
Audonnet Jean-Christophe,FRX ; Baudu Philippe,FRX, Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus.
Smith Gale E. ; Volvovitz Franklin ; Wilkinson Bethanie E. ; Voznesensky Andrei I. ; Hackett Craig S., Method for producing influenza hemagglutinin multivalent vaccines.
Smith Gale Eugene ; Volvovitz Franklin ; Wilkinson Bethanie Eident ; Hackett Craig Stanway, Method for producing influenza hemagglutinin multivalent vaccines using baculovirus.
Gail Eugene Smith ; James T. Matthews ; Edwin D. Kilbourne ; Bert E. Johansson ; Bethanie E. Wilkinson ; Andrei I. Voznesensky ; Craig S. Hackett ; Franklin Volvovitz, Neuraminidase-supplemented compositions.
David E. Briles ; Larry S. McDaniel ; Edwin Swiatlo ; Janet Yother ; Marilyn J. Crain ; Susan Hollingshead ; Rebecca Tart ; Alexis Brooks-Walter, Pneumococcal surface proteins and uses thereof.
Dale Beverly ; Yamanaka Miles ; Acree William M. ; Chavez ; Jr. Lloyd G., Recombinant structural and non-structural proteins of FIPV and method of immunizing.
Jean-Christophe Francis Audonnet FR; Philippe Guy Nicolas Baudu FR; Michel Albert Emile Riviere FR, Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis.
Smith Gale E. ; Foellmer Harald G. ; Knell John ; DeBartolomeis James ; Voznesensky Andrei I., Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using.
Smith Gale E. ; Volvovitz Franklin ; Wilkinson Bethanie E. ; Voznesensky Andrei I. ; Hackett Craig S., Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.